Testing whether the CaSR role was specific to MLL-AF9+ AML, we observed that transplantation of 5-fluorouracil-pre-treated CaSR KO BM cells, transduced with a retrovirus expressing the oncoprotein MN1 (Supplementary Fig. 12a), into WT recipients resulted in a lower tumour load (Supplementary Fig. 12b, c), a reduced percentage of MN1+ Gr1+ cells in PB (Supplementary Fig. 12d) and, similar to MLL-AF9+ AML, a significant survival prolongation compared to recipients of WT LIC (Supplementary Fig. 12e). This evidence concerns the gene CASR and acute myeloid leukemia.